Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

C. Poile · SciRah

Researcher profile · Semantic Scholar

C. Poile

Share profile

C. Poile — researcher profile on SciRah

h-index: 9
Works: 40
Citations: 596

Most-cited papers

Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial
D. Fennell, S. Ewings, C. Ottensmeier, R. Califano +35 more
2021The Lancet Oncology192 citations Open access
Semantic Scholar
Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment
Min Zhang, Jin-li Luo, Qianqian Sun, J. Harber +30 more
2021Nature Communications104 citations Open access
Semantic Scholar
A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study
E. Bancroft, E. Page, M. Brook, Sarah Thomas +314 more
2021The Lancet Oncology77 citations Open access
Semantic Scholar
Abemaciclib in patients with p16ink4A-deficient mesothelioma (MiST2): a single-arm, open-label, phase 2 trial.
D. Fennell, A. King, S. Mohammed, A. Greystoke +16 more
2022The Lancet Oncology63 citations Open access
Semantic Scholar
A gut microbiota rheostat forecasts responsiveness to PD-L1 and VEGF blockade in mesothelioma
Min Zhang, A. Bzura, E. Baitei, Zisen Zhou +40 more
2024Nature Communications32 citations Open access
Semantic Scholar
PS01.11 Nivolumab Versus Placebo in Relapsed Malignant Mesothelioma: The CONFIRM Phase 3 Trial
D. Fennell, C. Ottensmeier, R. Califano, G. Hanna +18 more
202129 citations Open access
Semantic Scholar
Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): A randomised, phase 2 trial
D. Fennell, Catharine Porter, J. Lester, S. Danson +13 more
2022EClinicalMedicine24 citations Open access
Semantic Scholar
A randomized phase II trial of oral vinorelbine as second-line therapy for patients with malignant pleural mesothelioma.
D. Fennell, A. Casbard, Catharine Porter, R. Rudd +14 more
202122 citations
Semantic Scholar
BAP1 loss induces mitotic defects in mesothelioma cells through BRCA1-dependent and independent mechanisms
Anita Singh, S. Busacca, A. Gaba, M. Sheaff +7 more
2022Oncogene13 citations Open access
Semantic Scholar
Constitutive inflammation and epithelial-mesenchymal transition dictate sensitivity to nivolumab in CONFIRM: a placebo-controlled, randomised phase III trial
D. Fennell, K. Hill, Min Zhang, C. Poile +36 more
2025Nature Communications7 citations Open access
Semantic Scholar
Bemcentinib and pembrolizumab in patients with relapsed mesothelioma: MIST3, a phase IIa trial with cellular and molecular correlates of efficacy.
M. Krebs, A. Branson, S. Barber, C. Poile +13 more
2023Journal of Clinical Oncology7 citations Open access
Semantic Scholar
Author Correction: Clonal architecture in mesothelioma is prognostic and shapes the tumour microenvironment
M. Zhang, Jin-li Luo, Qianqian Sun, J. Harber +30 more
2021Nature Communications5 citations Open access
Semantic Scholar
Gene fusions during the early evolution of mesothelioma correlate with impaired DNA repair and Hippo pathways
M. Jama, M. Zhang, C. Poile, A. Nakas +6 more
2023medRxiv4 citations Open access
Semantic Scholar
Evaluating niraparib versus active symptom control in patients with previously treated mesothelioma (NERO): a study protocol for a multicentre, randomised, two-arm, open-label phase II trial in UK secondary care centres
D. Fennell, Daniel Griffiths, Z. Eminton, Abigail Morgan-Fox +15 more
2023BMJ Open4 citations Open access
Semantic Scholar
MiST1: A phase IIa trial of rucaparib in patients harbouring BAP1/BRCA1 deficient relapsed malignant mesothelioma.
D. Fennell, L. Darlison, P. Wells-Jordan, C. Richards +14 more
20204 citations
Semantic Scholar
Discovery of actionable drug targets to enhance T-cell infiltration and immune checkpoint blockade efficacy in pleural mesothelioma.
J. V. van Genugten, D. Faulkner, J. Hahne, C. Poile +3 more
2025Lung Cancer3 citations
Semantic Scholar
Preclinical characterization and phase 1 clinical testing of targeting mitochondrial peroxiredoxin 3 in cancer
V. Gibson, Joanna Dzialo, T. Messier, A. Bzura +24 more
2026Nature Communications2 citations Open access
Semantic Scholar
Efficacy, cellular and molecular determinants of PD-1 checkpoint inhibition in relapsed mesothelioma.
D. Fennell, S. Ewings, K. Hill, C. Poile +16 more
2023Journal of Clinical Oncology2 citations
Semantic Scholar
Abstract CT263: Efficacy and multiomic analysis of Niraparib in relapsed mesothelioma: NERO a randomized phase II trial
D. Fennell, K. Hill, Z. Eminton, Daniel Griffiths +38 more
2025Cancer Research1 citations
Semantic Scholar
Niraparib and dostarlimab efficacy in patients with platinum-sensitive relapsed mesothelioma: MIST5, a phase IIa clinical trial.
Dean A. Fennell, A. Branson, A. King, C. Poile +11 more
2024Journal of Clinical Oncology1 citations
Semantic Scholar
61 The first-in-class peroxiredoxin 3 (PRX3) inhibitor RSO-021 modulates the mesenchymal and immune phenotype in mesothelioma
Brian Cunniff, T. Messier, V. Gibson, D. Seward +9 more
2024Lung Cancer1 citations
Semantic Scholar
Abstract 384: SLC7A11 modulates sensitivity to the first-in-class mitochondrial peroxiredoxin 3 inhibitor thiostrepton (RSO-021) via a ferroptosis independent pathway
T. Messier, V. Gibson, A. Bzura, Joanna Dzialo +6 more
2024Cancer Research1 citations
Semantic Scholar
A randomised phase II trial of niraparib versus active symptom control in patients with previously treated mesothelioma: NERO.
G. Griffiths, D. Griffiths, Z. Eminton, K. Hill +13 more
2023Journal of Clinical Oncology1 citations
Semantic Scholar
Tumour extrinsic neutrophil regulation in mesothelioma correlates with responsiveness to AXL and PD1 inhibition in MIST3, a phase IIA clinical trial
D. Fennell, J. Dzialo, M. Zhang, A. Bzura +43 more
2026medRxiv0 citations
Semantic Scholar
291 SynthEtic LEthal Cancer Therapy in mesothelioma (SELECTmeso): a molecularly stratified multi-arm phase II platform trial for patients with relapsed malignant mesothelioma
K. Hill, D. Fennell, Emma Knox, C. Middleton +10 more
2026Lung Cancer0 citations
Semantic Scholar
P2.307: SELECT Meso 1 Trial: A Phase II Trial of the MTA-cooperative PRMT5 Inhibitor BMS-986504 in Patients With MTAP-deficient Relapsed Mesothelioma
D. Fennell, E. Knox, M. Dungey, K. Hill +15 more
2026Journal of Thoracic Oncology0 citations
Semantic Scholar
Abstract 4039: Deletion of peroxiredoxin 3 (PRX3) impairs mitochondrial bioenergetics and tumor growth in mesothelioma, supporting the first in human clinical testing of the PRX3 inhibitor RSO-021
V. Gibson, Joanna Dzialo, C. Poile, J. Rogel +6 more
2026Cancer Research0 citations
Semantic Scholar
MO04.08: Tumour Extrinsic Regulation of Neutrophils Sensitize Mesotheliomas to AXL and PD1 Inhibition inMIST3, a Phase II Clinical Trial
D. Fennell, J. Dzialo, M. Zhang, A. Bzura +46 more
2026Journal of Thoracic Oncology0 citations
Semantic Scholar
Long-read Oxford Nanopore sequencing reveals complex rearrangements and regulatory disruption in malignant pleural mesothelioma
M. Alhazmi, C. Poile, J. Dzialo, A. Bzura +3 more
2026medRxiv0 citations Open access
Semantic Scholar
Abstract 4259: Peroxiredoxin 3 is a key regulator of mesothelioma progression and a target for therapeutic intervention
V. Gibson, J. Rogel, Joanna Dzialo, T. Messier +8 more
2025Cancer Research0 citations
Semantic Scholar
Abstract 3106: The first-in-class PRX3 inhibitor RSO-021 modulates the protein composition of malignant pleural effusions by increasing immunomodulating phenotypes and decreasing epithelial to mesenchymal protein expression
T. Messier, Bradley Cech, Joanna Dzialo, C. Poile +10 more
2025Cancer Research0 citations
Semantic Scholar
Abstract B041: Mitochondrial antioxidant peroxiredoxin 3 is a tractable therapeutic target in mesothelioma
V. Gibson, Joanna Dzialo, T. Messier, A. Bzura +21 more
2025Molecular Cancer Therapeutics0 citations
Semantic Scholar
208 SynthEtic LEthal Cancer Therapy in mesothelioma (SELECTmeso): a molecularly stratified multi-arm phase II platform trial for patients with relapsed malignant mesothelioma
K. Hill, D. Fennell, A. Song, R. Wickens +9 more
2024Lung Cancer0 citations
Semantic Scholar
Abstract 4716: First-in-class peroxiredoxin 3 (PRX3) inhibitor RSO-021 triggers mesenchymal-to-epithelial transition in mesothelioma
T. Messier, V. Gibson, David J. Seward, E. Baitei +9 more
2024Cancer Research0 citations
Semantic Scholar
Abstract 666: ASTX295 engages p53-mediated apoptosis and an inflammatory response in patient derived mesothelioma explants
D. Fennell, Joanna Dzialo, J. Rogel, Daniel Faulkner +11 more
2024Cancer Research0 citations
Semantic Scholar
Abstract C027: RSO-021, a first-in-class covalent inhibitor of mitochondrial PRX3: From bench to bedside
D. Fennell, S. Dulloo, P. Szlosarek, F. Thistlethwaite +11 more
2023Molecular Cancer Therapeutics0 citations
Semantic Scholar
A gut microbiota rheostat to forecast response to PDL1-VEGF blockade in mesothelioma.
D. Fennell, A. Bzura, A. Branson, A. King +15 more
2023Journal of Clinical Oncology0 citations
Semantic Scholar
Niraparib efficacy in patients with unresectable mesothelioma: a randomised phase II trial of niraparib versus active symptom control in patients with previously treated mesothelioma: NERO (TRIALS IN PROGRESS)
D. Fennell, D. Griffiths, Z. Eminton, Abigail Morgan-Fox +24 more
2023Lung Cancer0 citations
Semantic Scholar
Abstract 1613: Systematic screening for genomic vulnerabilities as drug targets for mesothelioma
G. Griffiths, D. James, Beth C. Dyson, Immaculate M. Nalubowa +17 more
2022Cancer Research0 citations
Semantic Scholar
Abstract 6086: Clonal biallelic inactivation of NF2 is an evolutionary bottleneck that exposes a vulnerability to CDK7 inhibition in mesothelioma
E. Baitei, Min Zhang, Qianqian Sun, Jin-li Luo +12 more
2022Cancer Research0 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

D. Fennell×25
Invite
D. Fennell — researcher profile on SciRah
A. Bzura×22
Invite
A. Bzura — researcher profile on SciRah
P. Wells-Jordan×19
Invite
P. Wells-Jordan — researcher profile on SciRah
A. Nakas×15
Invite
A. Nakas — researcher profile on SciRah

×13

Invite

Joanna Dzialo — researcher profile on SciRah

Invite

E. Baitei — researcher profile on SciRah

Invite

D. Fennell — researcher profile on SciRah

L. Darlison×11

Invite

L. Darlison — researcher profile on SciRah

C. Richards×10

Invite

C. Richards — researcher profile on SciRah

Invite

Jin-li Luo — researcher profile on SciRah

Invite

J. Rogel — researcher profile on SciRah

Invite

S. Dulloo — researcher profile on SciRah